BMY logo

BMY
Bristol-Myers Squibb Co.

20,639
Mkt Cap
$121.42B
Volume
3.9M
52W High
$62.89
52W Low
$42.52
PE Ratio
16.69
BMY Fundamentals
Price
$58.19
Prev Close
$59.46
Open
$59.70
50D MA
$58.40
Beta
0.32
Avg. Volume
9.68M
EPS (Annual)
$3.46
P/B
6.05
Rev/Employee
$1.48M
$146,482.66
Loading...
Loading...
News
all
press releases
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
News Placeholder
More News
News Placeholder
Here's Why You Should Add JANX Stock to Your Portfolio Now
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
News Placeholder
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
News Placeholder
Is Bristol-Myers Squibb (BMY) One of the Best Dividend Stocks to Invest in According to Hedge Funds?
Is Bristol-Myers Squibb (BMY) One of the Best Dividend Stocks to Invest in According to Hedge Funds...
News Placeholder
Bristol Myers Squibb to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 29 June 2 in Chicago, Illinois. Across more than 60 disclosures and 19 oral presentations, the...
News Placeholder
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
News Placeholder
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
Bristol Myers Squibb (NYSE:BMY, "BMS"), a global biopharmaceutical leader, today announced a strategic agreement with Anthropic to deploy Claude across the company's research, clinical development, manufacturing, commercial, and corporate functions. The collaboration signals a meaningful evolution...
News Placeholder
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
News Placeholder
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
News Placeholder
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available